TissueLink raises $20M for blood-loss products
TissueLink Medical, a Dover, N.H., developer of systems that limit blood loss during surgery, raised $20 million from insiders in a fifth funding round, VentureWire reports (subscription required).
From the VentureWire report:
Existing investors RiverVest Venture Partners and TLM Investors LLC, a group headed by Anthony Arnerich, chief executive of consultancy Arnerich Massena & Associates Inc. led the round, said John Landry, controller of TissueLink.
TissueLink’s coagulators and sealers use electric energy conducted through a saline solution to close up surgical incisions and stop bleeding in tissue and bone. The company, founded in 1999, named Joseph Army as its new CEO earlier this week, following the retirement of co-founder M. Jacqueline Eastwood.
Next Story: ONI Medical Systems secures $13M for MRI machines
Previous Story: Quark Pharma IPO delayed
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
